The Value Of Drug-Eluting Stents For Infrapopliteal Artery Lesions: A New Horizon, But Large Scale Randomized Trials Are Recommended
Main Category: Cardiovascular / CardiologyAlso Included In: Medical Devices / Diagnostics
Article Date: 24 Nov 2008 - 6:00 PDT
| Patient / Public: | ![]() |
3 (1 votes) |
| Healthcare Prof: | ![]() |
Recanalization of infrapopliteal arteries is important in patients with chronic limb ischemia to decrease limb-loss. Dr. Konstantinos Katsanos, of the Department of Radiology, Patras University Hospital School of Medicine, Patras, Greece, reviewed published data that highlighted the promising long-term limb salvage rates of below-the-knee angioplasty.
But, he noted re-occlusion following infrapopliteal angioplasty and stenting is identified in more than 50% of cases by 1 year thereby resulting in a high frequency of repeat procedures.
Drug-eluting stents (DES) have emerged as a potential solution to prevent restenosis from occurring. Dr. Katsanos reviewed studies that reported superior 6-month and 1-year angiographic and clinical performance of sirolimus-eluting stents (SES) versus bare metal stents (BMS) in terms of significantly reduced neointimal hyperplasia, higher angiographic primary patency and lower clinically driven re-intervention procedures.
He concluded that infrapopliteal SES for CLI significantly improve primary patency and reduce infrapopliteal vascular restenosis thereby lessening the rate of clinically driven repeat procedures. Dr. Katsanos cautions, however, that large-scale multicenter randomized trials are required to further investigate the role of infrapopliteal SES in CLI treatment prior to widespread adoption of this technology.
VEITH SYMPOSIUM - New York, November 19th to 23rd
Now in its fourth decade, VEITH SYMPOSIUM provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques.
VEITHsymposium is sponsored by Cleveland Clinic, Cleveland, OH.
www.veithsymposium.org
Source
Pauline T. Mayer
www.ptmhcm.com
Visit our cardiovascular / cardiology section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/130507.php>
APA
http://www.medicalnewstoday.com/releases/130507.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





